The Impact of Norepinephrine on Pulmonary Vein in Treating Septic Shock_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

SUO Liangyuan ,  ZHANG Jin

Department of anesthesiology, shengjin Hospital Affiliated to Chinese medical university. Shenyang, 110003, China;

Corresponding author：

ZHANG Jin, Email: zhangj1@sj-hospital.org

Keywords：

感染性休克; 去甲肾上腺素; 肺静脉; 血管阻力

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： SUO Liangyuan,ZHANG Jin. The Impact of Norepinephrine on Pulmonary Vein in Treating Septic Shock. Chinese Journal of Respiratory and Critical Care Medicine, 2009, 09(3): 303-306. doi: Copy

1.	Liaudet L, Szabo C, Evgenov OV, et al. Flagellin from Gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock, 2003, 19: 131-137.
2.	Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet, 2007, 370: 676-684.
3.	Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med, 2000, 28: 2758-2765.
4.	De Backer D, Creteur J, Silva E, et al. Effects of dopamine,norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med, 2003 , 31 : 1659-1667.
5.	Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous wasopressin infusion in catecholamineresistant wasodilatory shock: incidence and risk factor. Crit Care Med, 2003, 31: 1394-1398.
6.	Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med, 2008, 34: 17-60.
7.	Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 1997 ,95: 1122-1125.
8.	林爱华, 郭凤梅. 血管活性药物对感染性休克患者动脉血乳酸的影响. 齐齐哈尔医学院学报, 2005, 26: 888-889.
9.	LauzierF,Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.Intensive Care Med, 2006, 32: 1782-1789.
10.	Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med, 2001, 29: 1526-1531.
11.	Martin C, Viviand X, Arnaud S, et al. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med, 1999, 27: 1708-1713.
12.	Muthalif MM, Uddin MR, Fatima S, et al. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid Mediat, 2001, 65:33-43.
13.	Walch L, Labat C, Gascard JP, et al. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol,1999, 126: 859-866.
14.	Vaz-da-Silva MJ, Magina S, Domingues-Costa A, et al. The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle.Br J Pharmacol, 1996, 118: 364-368.
15.	Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature, 1983, 305: 627-630.
16.	Miller VM, Vanhoutte PM. Endothelial alpha 2 -adrenoceptors in canine pulmonary and systemic blood vessels. Eur J Pharmacol,1985, 118: 123-129.
17.	Guimar　S,Moura D. Vascular adrenoceptors: an update. Pharmacol Rev, 2001, 53: 319-356.
18.	Bockman CS, Jeffries WB, Abel PW. Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther, 1993, 267: 1126-1133.
19.	Janssen LJ, Lu-Chao H, Netherton S. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am J Physiol Lung Cell Mol Physiol, 2001 , 280: L666 -L674.
20.	Ding X, Murray PA. Cellular mechanisms of thromboxane A2 -mediated contraction in pulmonary veins. Am J Physiol Lung Cell Mol Physiol, 2005, 289: L825-L833.
21.	Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev, 1994 ,46: 121-136.
22.	Blaylock NA, Wilson VG. Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar common digital artery. Br J Pharmacol, 1995, 114: 694-702.
23.	G　rnemann T, von Wenckstern H, Kleuser B, et al. Characterization of the postjunctional alpha 2C-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins. Br J Pharmacol, 2007, 151: 186-194.
24.	Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smoothmuscle and non-muscle myosin. J Physiol, 2000, 522: 177 -185.
25.	Okabe K, Kitamura K, Kuriyam K. Features of 4- aminopyr-idinesensitive outward current observed in single smooth mus-cle cells from the rabbit pulmonary artery. Pflugers Arch,1987, 409: 561-568.
26.	Petitcolin MA, Spitzbarth-Régrigny E, Bueb JL, et al. Role of Giproteins in norepinephrine-mediated vasoconstriction in rat tail artery smooth muscle. Biochem Pharmacol, 2001, 61: 1169-1175.
27.	Atkinson J, Trescases N, Benedek C, et al. Alpha-1 and alpha-2 adrenoceptor agonists induce vasoconstriction of the normotensive rat caudal artery in vitro by stimulation of a heterogeneous population of alpha-1 adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol,1988, 338: 529-535.
28.	Zhong H, Minneman KP. Alpha1 -adrenoceptor subtypes. Eur J Pharmacol, 1999, 375: 261-276.
29.	Hallemeesch MM, Janssen BJ, de Jonge WJ, et al. NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice. Am J Physiol Endocrinol Metab, 2003, 285: E871-E875.
30.	Ding X, Murray PA. Regulation of pulmonary venous tone in response to muscarinic receptor activation. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L131-L140.
31.	段国辰, 凌亦凌, 谷振勇, 等. 八肽胆囊收缩素对家兔内毒素休克时主动脉及肺动脉反应性改变的影响. 中国急救医学, 2002,22: 693-697.
32.	Schmeck J, Heller A, Gr　schler A, et al. Impact of endothelin-1 in endotoxin-induced pulmonary vascular reactions. Crit Care Med, 2000, 28: 2851-2857.
33.	裴凌, 王俊科, 傅文, 等. 肿瘤坏死因子-α损伤的肺动脉内皮细胞对肺动脉平滑肌细胞增殖的影响及内皮细胞热应激反应的干扰作用. 中华麻醉学杂志, 2000, 20: 47-50.
34.	Zhang RZ, Yang Q, YimAP, et al. Role of NO and EDHF-mediated endothelial function in the porcine pulmonary circulation:comparison between pulmonary artery and vein. Vascular Pharmacology, 2006, 44: 183-191.
35.	Ding X, Murray PA. Regulation of pulmonary venous tone in response to muscarinic receptor activation. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L131-L140.
36.	Angle MR, Molloy DW, Penner B, et al. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest, 1989, 95: 1333-1337.
37.	D′Ambra MN, LaRaia PJ, Philbin DM, et al. Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg, 1985, 89: 567-572.

1. Liaudet L, Szabo C, Evgenov OV, et al. Flagellin from Gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock, 2003, 19: 131-137.
2. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet, 2007, 370: 676-684.
3. Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med, 2000, 28: 2758-2765.
4. De Backer D, Creteur J, Silva E, et al. Effects of dopamine,norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med, 2003 , 31 : 1659-1667.
5. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous wasopressin infusion in catecholamineresistant wasodilatory shock: incidence and risk factor. Crit Care Med, 2003, 31: 1394-1398.
6. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med, 2008, 34: 17-60.
7. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 1997 ,95: 1122-1125.
8. 林爱华, 郭凤梅. 血管活性药物对感染性休克患者动脉血乳酸的影响. 齐齐哈尔医学院学报, 2005, 26: 888-889.
9. LauzierF,Lévy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.Intensive Care Med, 2006, 32: 1782-1789.
10. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med, 2001, 29: 1526-1531.
11. Martin C, Viviand X, Arnaud S, et al. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med, 1999, 27: 1708-1713.
12. Muthalif MM, Uddin MR, Fatima S, et al. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid Mediat, 2001, 65:33-43.
13. Walch L, Labat C, Gascard JP, et al. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol,1999, 126: 859-866.
14. Vaz-da-Silva MJ, Magina S, Domingues-Costa A, et al. The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle.Br J Pharmacol, 1996, 118: 364-368.
15. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature, 1983, 305: 627-630.
16. Miller VM, Vanhoutte PM. Endothelial alpha 2 -adrenoceptors in canine pulmonary and systemic blood vessels. Eur J Pharmacol,1985, 118: 123-129.
17. Guimar　S,Moura D. Vascular adrenoceptors: an update. Pharmacol Rev, 2001, 53: 319-356.
18. Bockman CS, Jeffries WB, Abel PW. Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther, 1993, 267: 1126-1133.
19. Janssen LJ, Lu-Chao H, Netherton S. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am J Physiol Lung Cell Mol Physiol, 2001 , 280: L666 -L674.
20. Ding X, Murray PA. Cellular mechanisms of thromboxane A2 -mediated contraction in pulmonary veins. Am J Physiol Lung Cell Mol Physiol, 2005, 289: L825-L833.
21. Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev, 1994 ,46: 121-136.
22. Blaylock NA, Wilson VG. Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar common digital artery. Br J Pharmacol, 1995, 114: 694-702.
23. G　rnemann T, von Wenckstern H, Kleuser B, et al. Characterization of the postjunctional alpha 2C-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins. Br J Pharmacol, 2007, 151: 186-194.
24. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smoothmuscle and non-muscle myosin. J Physiol, 2000, 522: 177 -185.
25. Okabe K, Kitamura K, Kuriyam K. Features of 4- aminopyr-idinesensitive outward current observed in single smooth mus-cle cells from the rabbit pulmonary artery. Pflugers Arch,1987, 409: 561-568.
26. Petitcolin MA, Spitzbarth-Régrigny E, Bueb JL, et al. Role of Giproteins in norepinephrine-mediated vasoconstriction in rat tail artery smooth muscle. Biochem Pharmacol, 2001, 61: 1169-1175.
27. Atkinson J, Trescases N, Benedek C, et al. Alpha-1 and alpha-2 adrenoceptor agonists induce vasoconstriction of the normotensive rat caudal artery in vitro by stimulation of a heterogeneous population of alpha-1 adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol,1988, 338: 529-535.
28. Zhong H, Minneman KP. Alpha1 -adrenoceptor subtypes. Eur J Pharmacol, 1999, 375: 261-276.
29. Hallemeesch MM, Janssen BJ, de Jonge WJ, et al. NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice. Am J Physiol Endocrinol Metab, 2003, 285: E871-E875.
30. Ding X, Murray PA. Regulation of pulmonary venous tone in response to muscarinic receptor activation. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L131-L140.
31. 段国辰, 凌亦凌, 谷振勇, 等. 八肽胆囊收缩素对家兔内毒素休克时主动脉及肺动脉反应性改变的影响. 中国急救医学, 2002,22: 693-697.
32. Schmeck J, Heller A, Gr　schler A, et al. Impact of endothelin-1 in endotoxin-induced pulmonary vascular reactions. Crit Care Med, 2000, 28: 2851-2857.
33. 裴凌, 王俊科, 傅文, 等. 肿瘤坏死因子-α损伤的肺动脉内皮细胞对肺动脉平滑肌细胞增殖的影响及内皮细胞热应激反应的干扰作用. 中华麻醉学杂志, 2000, 20: 47-50.
34. Zhang RZ, Yang Q, YimAP, et al. Role of NO and EDHF-mediated endothelial function in the porcine pulmonary circulation:comparison between pulmonary artery and vein. Vascular Pharmacology, 2006, 44: 183-191.
35. Ding X, Murray PA. Regulation of pulmonary venous tone in response to muscarinic receptor activation. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L131-L140.
36. Angle MR, Molloy DW, Penner B, et al. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest, 1989, 95: 1333-1337.
37. D′Ambra MN, LaRaia PJ, Philbin DM, et al. Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg, 1985, 89: 567-572.

Chinese Journal of Respiratory and Critical Care Medicine

The Impact of Norepinephrine on Pulmonary Vein in Treating Septic Shock

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content